Genmab (CPH:GEN)

FierceBiotech  Jun 9  Comment 
Genmab hits new highs as ASCO data bolster case for J&J-partnered cancer drug ntaylor Thu, 06/09/2016 - 06:07  Jun 2  Comment 
BASEL (dpa-AFX) - Genmab A/S (GMXAY.PK, GNMSF.OB) said that its collaboration partner Novartis will start Phase III studies of the subcutaneous formulation of ofatumumab in relapsing multiple sclerosis or MS with enrolment of patients expected to...
FierceBiotech  Jun 1  Comment 
Genmab bags $30M milestone from J&J as Darzalex money machine fires up ntaylor Wed, 06/01/2016 - 05:09
SeekingAlpha  May 11  Comment 
SeekingAlpha  May 10  Comment 
Reuters  Apr 20  Comment 
Danish biotech company Genmab raised its financial guidance for 2016 on Wednesday due to "robust" sales of its blood cancer drug Darzalex since it was launched in...
FierceBiotech  Apr 7  Comment 
MorphoSys has initiated legal action against Genmab and Johnson & Johnson's Janssen Biotech. The case relates to Darzalex, Genmab and Janssen's multiple myeloma drug that MorphoSys claims infringes on its patent covering antibodies with certain...
FierceBiotech  Mar 10  Comment 
In this week's EuroBiotech Report, having weighed up its options for Arzerra, the Genmab drug it recently acquired from GlaxoSmithKline, Novartis is halting a Phase III trial in pemphigus vulgaris to go all in on the big prize: relapsing multiple...
FierceBiotech  Mar 10  Comment 
Novartis has stopped a Phase III trial of Genmab's Arzerra in pemphigus vulgaris patients. The decision, which comes seven months after Novartis agreed to buy the rights to Arzerra in autoimmune indications from GlaxoSmithKline, will result in a...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki